David Corcoran1,2, Aleksandra Radjenovic1, Ify R Mordi1,2, Sheraz A Nazir3, Simon J Wilson4, Markus Hinder5, Denise P Yates6, Surendra Machineni7, Jose Alcantara5, Margaret F Prescott8, Barbara Gugliotta5, Yinuo Pang6, Niko Tzemos9, Scott I Semple4, David E Newby4, Gerry P McCann3, Iain Squire3, Colin Berry1,2. 1. British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK. 2. Golden Jubilee National Hospital, Glasgow, UK. 3. Department of Cardiovascular Sciences, University of Leicester and NIHR Leicester Biomedical Research Centre, Leicester, UK. 4. British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK. 5. Novartis Institutes for Biomedical Research, Basel, Switzerland. 6. Novartis Institutes for BioMedical Research, Cambridge, MA, USA. 7. Novartis Healthcare Private Limited, Hyderabad, India. 8. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. 9. London Health Science Centre, University of Western Ontario, London, Ontario, Canada.
Abstract
AIMS: The effects of serelaxin, a recombinant form of human relaxin-2 peptide, on vascular function in the coronary microvascular and systemic macrovascular circulation remain largely unknown. This mechanistic, clinical study assessed the effects of serelaxin on myocardial perfusion, aortic stiffness, and safety in patients with stable coronary artery disease (CAD). METHODS AND RESULTS: In this multicentre, double-blind, parallel-group, placebo-controlled study, 58 patients were randomized 1:1 to 48 h intravenous infusion of serelaxin (30 µg/kg/day) or matching placebo. The primary endpoints were change from baseline to 47 h post-initiation of the infusion in global myocardial perfusion reserve (MPR) assessed using adenosine stress perfusion cardiac magnetic resonance imaging, and applanation tonometry-derived augmentation index (AIx). Secondary endpoints were: change from baseline in AIx and pulse wave velocity, assessed at 47 h, Day 30, and Day 180; aortic distensibility at 47 h; pharmacokinetics and safety. Exploratory endpoints were the effect on cardiorenal biomarkers [N-terminal pro-brain natriuretic peptide (NT-proBNP), high-sensitivity troponin T (hsTnT), endothelin-1, and cystatin C]. Of 58 patients, 51 were included in the primary analysis (serelaxin, n = 25; placebo, n = 26). After 2 and 6 h of serelaxin infusion, mean placebo-corrected blood pressure reductions of -9.6 mmHg (P = 0.01) and -13.5 mmHg (P = 0.0003) for systolic blood pressure and -5.2 mmHg (P = 0.02) and -8.4 mmHg (P = 0.001) for diastolic blood pressure occurred. There were no between-group differences from baseline to 47 h in global MPR (-0.24 vs. -0.13, P = 0.44) or AIx (3.49% vs. 0.04%, P = 0.21) with serelaxin compared with placebo. Endothelin-1 and cystatin C levels decreased from baseline in the serelaxin group, and there were no clinically relevant changes observed with serelaxin for NT-proBNP or hsTnT. Similar numbers of serious adverse events were observed in both groups (serelaxin, n = 5; placebo, n = 7) to 180-day follow-up. CONCLUSION: In patients with stable CAD, 48 h intravenous serelaxin reduced blood pressure but did not alter myocardial perfusion.
RCT Entities:
AIMS: The effects of serelaxin, a recombinant form of humanrelaxin-2 peptide, on vascular function in the coronary microvascular and systemic macrovascular circulation remain largely unknown. This mechanistic, clinical study assessed the effects of serelaxin on myocardial perfusion, aortic stiffness, and safety in patients with stable coronary artery disease (CAD). METHODS AND RESULTS: In this multicentre, double-blind, parallel-group, placebo-controlled study, 58 patients were randomized 1:1 to 48 h intravenous infusion of serelaxin (30 µg/kg/day) or matching placebo. The primary endpoints were change from baseline to 47 h post-initiation of the infusion in global myocardial perfusion reserve (MPR) assessed using adenosine stress perfusion cardiac magnetic resonance imaging, and applanation tonometry-derived augmentation index (AIx). Secondary endpoints were: change from baseline in AIx and pulse wave velocity, assessed at 47 h, Day 30, and Day 180; aortic distensibility at 47 h; pharmacokinetics and safety. Exploratory endpoints were the effect on cardiorenal biomarkers [N-terminal pro-brain natriuretic peptide (NT-proBNP), high-sensitivity troponin T (hsTnT), endothelin-1, and cystatin C]. Of 58 patients, 51 were included in the primary analysis (serelaxin, n = 25; placebo, n = 26). After 2 and 6 h of serelaxin infusion, mean placebo-corrected blood pressure reductions of -9.6 mmHg (P = 0.01) and -13.5 mmHg (P = 0.0003) for systolic blood pressure and -5.2 mmHg (P = 0.02) and -8.4 mmHg (P = 0.001) for diastolic blood pressure occurred. There were no between-group differences from baseline to 47 h in global MPR (-0.24 vs. -0.13, P = 0.44) or AIx (3.49% vs. 0.04%, P = 0.21) with serelaxin compared with placebo. Endothelin-1 and cystatin C levels decreased from baseline in the serelaxin group, and there were no clinically relevant changes observed with serelaxin for NT-proBNP or hsTnT. Similar numbers of serious adverse events were observed in both groups (serelaxin, n = 5; placebo, n = 7) to 180-day follow-up. CONCLUSION: In patients with stable CAD, 48 h intravenous serelaxin reduced blood pressure but did not alter myocardial perfusion.
Authors: Jacqueline Novak; Rolando J J Ramirez; Robin E Gandley; O David Sherwood; Kirk P Conrad Journal: Am J Physiol Regul Integr Comp Physiol Date: 2002-08 Impact factor: 3.619
Authors: Joris van Drongelen; Ivo H J Ploemen; Jeanne Pertijs; Jonathan H Gooi; Fred C G J Sweep; Frederik K Lotgering; Marc E A Spaanderman; Paul Smits Journal: Am J Physiol Heart Circ Physiol Date: 2011-02-18 Impact factor: 4.733
Authors: Marco Metra; John R Teerlink; Gad Cotter; Beth A Davison; G Michael Felker; Gerasimos Filippatos; Barry H Greenberg; Peter S Pang; Piotr Ponikowski; Adriaan A Voors; Kirkwood F Adams; Stefan D Anker; Alexandra Arias-Mendoza; Patricio Avendaño; Fernando Bacal; Michael Böhm; Guillermo Bortman; John G F Cleland; Alain Cohen-Solal; Maria G Crespo-Leiro; Maria Dorobantu; Luis E Echeverría; Roberto Ferrari; Sorel Goland; Eva Goncalvesová; Assen Goudev; Lars Køber; Juan Lema-Osores; Phillip D Levy; Kenneth McDonald; Pravin Manga; Béla Merkely; Christian Mueller; Burkert Pieske; Jose Silva-Cardoso; Jindřich Špinar; Iain Squire; Janina Stępińska; Walter Van Mieghem; Dirk von Lewinski; Gerhard Wikström; Mehmet B Yilmaz; Nicole Hagner; Thomas Holbro; Tsushung A Hua; Shalini V Sabarwal; Thomas Severin; Peter Szecsödy; Claudio Gimpelewicz Journal: N Engl J Med Date: 2019-08-22 Impact factor: 91.245
Authors: Gary F Mitchell; Shih-Jen Hwang; Ramachandran S Vasan; Martin G Larson; Michael J Pencina; Naomi M Hamburg; Joseph A Vita; Daniel Levy; Emelia J Benjamin Journal: Circulation Date: 2010-01-18 Impact factor: 29.690
Authors: R A D Bathgate; E D Lekgabe; J T McGuane; Y Su; T Pham; T Ferraro; S Layfield; R D Hannan; W G Thomas; C S Samuel; X-J Du Journal: Mol Cell Endocrinol Date: 2007-09-22 Impact factor: 4.102
Authors: Thomas Dschietzig; Sam Teichman; Elaine Unemori; Susy Wood; Julia Boehmer; Christoph Richter; Gert Baumann; Karl Stangl Journal: J Card Fail Date: 2009-03-09 Impact factor: 5.712
Authors: Rohan Jagathesan; Stuart D Rosen; Rodney A Foale; Paolo G Camici; Eugenio Picano Journal: J Cardiovasc Pharmacol Date: 2006-09 Impact factor: 3.105